Want to join the conversation?
$ENDP 2Q15 Call: We continue to make good progress in addressing strategic priorities that will support us to become a global specialty pharmaceutical company. Our US generics business delivered strong underlying growth in 1H15.Generic VALCYTE continues to be highlight among new products &contributed to double-digit volume growth from base business
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.